Bert Strookappe1,2, Jeff Swigris3, Jolanda De Vries2,4, Marjon Elfferich2, Ton Knevel1, Marjolein Drent5,6,7. 1. Department of Physical Therapy, Hospital Gelderse Vallei (ZGV), Ede, The Netherlands. 2. ild care foundation research team, PO Box 18, 6720 AA, Bennekom, The Netherlands. 3. Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, Denver, CO, USA. 4. Department of Medical Psychology, St. Elisabeth Hospital Tilburg and Department of Medical and Clinical Psychology, CoRPS, Tilburg University, Tilburg, The Netherlands. 5. ild care foundation research team, PO Box 18, 6720 AA, Bennekom, The Netherlands. m.drent@maastrichtuniversity.nl. 6. Center of Interstitial Lung Diseases, St. Antonius Hospital, Nieuwegein, The Netherlands. m.drent@maastrichtuniversity.nl. 7. Department of Pharmacology and Toxicology, Faculty of Health, Medicine and Life Science, Maastricht University, Maastricht, The Netherlands. m.drent@maastrichtuniversity.nl.
Abstract
BACKGROUND: Sarcoidosis patients suffer from fatigue and exercise limitation. The aim of this study was to establish whether a physical training program improves these and other outcomes important to sarcoidosis patients. METHODS: From 11/2012 to 9/2014, 201 sarcoidosis patients were referred to the ild care expertise team, Ede, the Netherlands. In our center, all patients are routinely recommended to undergo testing at baseline to determine their physical functioning and encouraged to complete a 12-week, supervised physical training program. Ninety patients underwent baseline testing and returned for repeat testing at 3 months in the interim, 49 completed the training program (Group I) and 41 chose not to participate (Group II). Change over time (from baseline to 3 months) in fatigue, exercise capacity, and skeletal muscle strength were assessed between the two groups. RESULTS: At baseline, there were no between-group differences for fatigue, DLCO%, FVC%, or exercise capacity [assessed by percent predicted six-minute walk distance (6MWD%) and Steep Ramp Test (SRT)]. The 6MWD for Group I improved between baseline and 3 months, while the 6MWD remained the same in Group II (F = 72.2, p < 0.001). Group I showed a significantly larger decrease of fatigue compared with Group II (F = 6.27, p = 0.014). Lung function tests did not change in either group. CONCLUSION: A supervised physical training program improves exercise capacity and fatigue among sarcoidosis patients and should be included in their management regimen.
BACKGROUND:Sarcoidosispatients suffer from fatigue and exercise limitation. The aim of this study was to establish whether a physical training program improves these and other outcomes important to sarcoidosispatients. METHODS: From 11/2012 to 9/2014, 201 sarcoidosispatients were referred to the ild care expertise team, Ede, the Netherlands. In our center, all patients are routinely recommended to undergo testing at baseline to determine their physical functioning and encouraged to complete a 12-week, supervised physical training program. Ninety patients underwent baseline testing and returned for repeat testing at 3 months in the interim, 49 completed the training program (Group I) and 41 chose not to participate (Group II). Change over time (from baseline to 3 months) in fatigue, exercise capacity, and skeletal muscle strength were assessed between the two groups. RESULTS: At baseline, there were no between-group differences for fatigue, DLCO%, FVC%, or exercise capacity [assessed by percent predicted six-minute walk distance (6MWD%) and Steep Ramp Test (SRT)]. The 6MWD for Group I improved between baseline and 3 months, while the 6MWD remained the same in Group II (F = 72.2, p < 0.001). Group I showed a significantly larger decrease of fatigue compared with Group II (F = 6.27, p = 0.014). Lung function tests did not change in either group. CONCLUSION: A supervised physical training program improves exercise capacity and fatigue among sarcoidosispatients and should be included in their management regimen.
Authors: A W E Braam; S N de Haan; A D M Vorselaars; G T Rijkers; J C Grutters; F J J van den Elshout; I H E Korenromp Journal: Brain Behav Immun Date: 2013-05-29 Impact factor: 7.217
Authors: Rik G J Marcellis; Antoine F Lenssen; Geeuwke J de Vries; Robert P Baughman; Chris P van der Grinten; Johny A Verschakelen; Jolanda De Vries; Marjolein Drent Journal: Lung Date: 2012-11-09 Impact factor: 2.584
Authors: Martijn A Spruit; Sally J Singh; Chris Garvey; Richard ZuWallack; Linda Nici; Carolyn Rochester; Kylie Hill; Anne E Holland; Suzanne C Lareau; William D-C Man; Fabio Pitta; Louise Sewell; Jonathan Raskin; Jean Bourbeau; Rebecca Crouch; Frits M E Franssen; Richard Casaburi; Jan H Vercoulen; Ioannis Vogiatzis; Rik Gosselink; Enrico M Clini; Tanja W Effing; François Maltais; Job van der Palen; Thierry Troosters; Daisy J A Janssen; Eileen Collins; Judith Garcia-Aymerich; Dina Brooks; Bonnie F Fahy; Milo A Puhan; Martine Hoogendoorn; Rachel Garrod; Annemie M W J Schols; Brian Carlin; Roberto Benzo; Paula Meek; Mike Morgan; Maureen P M H Rutten-van Mölken; Andrew L Ries; Barry Make; Roger S Goldstein; Claire A Dowson; Jan L Brozek; Claudio F Donner; Emiel F M Wouters Journal: Am J Respir Crit Care Med Date: 2013-10-15 Impact factor: 21.405
Authors: Elliott D Crouser; Rachel M Smith; Daniel A Culver; Mark W Julian; Karen Martin; Joanne Baran; Christopher Diaz; Barbaros Selnur Erdal; Erinn M Hade Journal: Chest Date: 2021-05-23 Impact factor: 10.262
Authors: M J G van Manen; V L Wester; E F C van Rossum; L M van den Toorn; K Y Dorst; Y B de Rijke; M S Wijsenbeek Journal: PLoS One Date: 2019-06-14 Impact factor: 3.240
Authors: C C Moor; M J G van Manen; P M van Hagen; J R Miedema; L M van den Toorn; Y Gür-Demirel; A P C Berendse; J A M van Laar; M S Wijsenbeek Journal: Lung Date: 2018-08-07 Impact factor: 2.584